एपीए उद्धरण

Fishman, M. (2019). Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer (“KEYNOTE 045”). Transl Androl Urol.

शिकागो स्टाइल उद्धरण

Fishman, Mayer. "Commentary: 2-year Follow Up of Pembrolizumab As Second-line Therapy for Advanced Urothelial Cancer (“KEYNOTE 045”)." Transl Androl Urol 2019.

एमएलए उद्धरण

Fishman, Mayer. "Commentary: 2-year Follow Up of Pembrolizumab As Second-line Therapy for Advanced Urothelial Cancer (“KEYNOTE 045”)." Transl Androl Urol 2019.